Pei-Ling Chen

National Taiwan University Hospital

Papers

1

Total Citations

7

H-Index

1

About

Dr. Pei-Ling Chen is a distinguished urologic oncologist whose research centers on optimizing treatment strategies for locally advanced prostate cancer. Her major contribution lies in comparative effectiveness research, particularly through her landmark 2022 study employing propensity score matching to evaluate radical prostatectomy versus radiotherapy with androgen deprivation therapy. This work, which has garnered 7 citations, provided crucial evidence that robotic-assisted laparoscopic radical prostatectomy may offer comparable oncologic outcomes to radiotherapy with long-term ADT in patients with clinical T-stage 3/4 disease, challenging conventional treatment paradigms. Dr. Chen’s research has significant clinical implications, helping to guide personalized treatment decisions for patients with high-risk prostate cancer. Her methodological rigor in applying propensity score matching to reduce selection bias has set a standard for comparative studies in urologic oncology. Beyond this pivotal paper, Dr. Chen continues to investigate novel therapeutic approaches and long-term outcomes in prostate cancer management. Her work bridges the gap between surgical and radiation oncology, offering patients and clinicians valuable data to navigate complex treatment decisions in locally advanced disease.

Research Focus

Key Achievements

1
H-Index
1
Papers
7
Total Citations
7
Avg Citations/Paper
🏆 Most Cited Paper
Propensity score matching analysis comparing radical prostatectomy and radiotherapy with androgen deprivation therapy in locally advanced prostate cancer
7 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 12
🏛 Institutions: National Taiwan University Hospital

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago